Corinne A Betts

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7458446/publications.pdf

Version: 2024-02-01

16	871	840119 11	887659 17
papers	citations	h-index	g-index

17	17	17	1291
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dystrophin involvement in peripheral circadian SRF signalling. Life Science Alliance, 2021, 4, e202101014.	1.3	1
2	Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 578-593.	2.9	24
3	Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment. Human Molecular Genetics, 2019, 28, 396-406.	1.4	10
4	Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment. Nucleic Acid Therapeutics, 2019, 29, 1-12.	2.0	70
5	Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice. Human Molecular Genetics, 2018, 27, 3582-3597.	1.4	10
6	Interventions Targeting Glucocorticoid-KrÃ¼ppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. EBioMedicine, 2018, 31, 226-242.	2.7	37
7	Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy. PLoS ONE, 2018, 13, e0198897.	1.1	19
8	Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation. Human Molecular Genetics, 2016, 25, 3960-3974.	1.4	50
9	Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Scientific Reports, 2015, 5, 8986.	1.6	43
10	Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy. Scientific Reports, 2015, 5, 11632.	1.6	12
11	Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Scientific Reports, 2015, 5, 17014.	1.6	50
12	How much dystrophin is enough: the physiological consequences of different levels of dystrophin in themdxmouse. Human Molecular Genetics, 2015, 24, 4225-4237.	1.4	116
13	Delivery of therapeutic oligonucleotides with cell penetrating peptides. Advanced Drug Delivery Reviews, 2015, 87, 52-67.	6.6	217
14	Cell Penetrating Peptide Delivery of Splice Directing Oligonucleotides as a Treatment for Duchenne Muscular Dystrophy. Current Pharmaceutical Design, 2013, 19, 2948-2962.	0.9	22
15	Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Molecular Therapy - Nucleic Acids, 2012, 1, e38.	2.3	177
16	Optimizing Tissue-Specific Antisense Oligonucleotideâ€“Peptide Conjugates. Methods in Molecular Biology, 2012, 867, 415-435.	0.4	8